Abera Bioscience AB is a Sweden-based company, which is active in biotechnology. Abera Bioscience is platform and vaccine development company active in the medical, molecular and microbiological field. The Companyâ€™s purpose is to develop vaccine candidates based on its vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and immunooncology. The business is located around the Nordic market.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-28	SEK 8.140	-0.25%	2,867
26-08-27	SEK 8.160	-0.73%	1,235
26-08-26	SEK 8.220	+0.49%	411
26-08-25	SEK 8.180	+0.49%	330
26-08-24	SEK 8.140	-1.45%	10,463

End-of-day quote NORDIC GROWTH MARKET

More quotes

Net sales - Rate of surprise

Company calendar

End-of-day quote NORDIC GROWTH MARKET 2026-08-28			5-day change	1st Jan Change
8.140 ^SEK	-0.25%		-1.45%	+19.71%

08-20	Abera Bioscience widens operating loss, 'working intensively to broaden the pipeline', CEO says	FW
08-20	Abera Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	167M 17.42M 15M 14.08M 12.85M 24.15M 1.66B 24.32M 64.92M 840M 65.4M 63.98M 2.78B	P/E 2024	-64.4x	P/E 2025	-10.8x
Enterprise Value	143M 14.97M 12.89M 12.1M 11.04M 20.75M 1.42B 20.9M 55.78M 722M 56.19M 54.97M 2.39B	EV / Sales 2024	4.32x	EV / Sales 2025	8.6x
Free-Float	40.83%	Yield 2024 *	-	Yield 2025	-

08-20	Abera Bioscience widens operating loss, 'working intensively to broaden the pipeline', CEO says	FW
08-20	Abera Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Abera Bioscience raises SEK 7.9m after warrant exercise	FW
07-22	Abera Bioscience applies to begin Phase I study of vaccine candidate	FW
07-20	Abera Biosciences management and staff buy stock options from board member	FW
06-30	Abera Bioscience reports results from ferret study	FW
06-16	CEPI extends support for Abera vaccine project	FW
06-08	Abera Bioscience completes production ahead of clinical trial for vaccine candidate	FW
05-12	Abera Bioscience reports operating loss in Q1	FW
05-12	Abera Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Abera Bioscience vaccine technology bolstered by scientific publication	FW
02-12	Abera Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-12	Abera Bioscience Swings to Operating Loss, 'Vaccine Candidate Development Continues as Planned' - CEO	FW

24-08-30	Carlsquare lowers motivated value for Abera Bioscience	FW
24-05-23	Carlsquare lowers the motivated value for Abera Bioscience	FW
23-11-16	Carlsquare raises motivated value for Abera Bioscience slightly to SEK 11.80	FW

Abera Bioscience AB Stock

Stocks

ABERA

SE0015245097

Biotechnology & Medical Research

Valuation : Abera Bioscience AB

Chart: Abera Bioscience AB

Latest news : Abera Bioscience AB

Analysts' recommendations : Abera Bioscience AB

Press Releases : Abera Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors : Abera Bioscience AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

1 day	-0.25%
1 week	-1.45%
Current month	-3.10%
1 month	-3.10%
3 months	+14.65%
6 months	+34.55%
Current year	+19.71%

1 week	7.82	8.22
1 month	7.82	8.94
Current year	5.15	10.05
1 year	5.15	10.05
3 years	3.24	10.05
5 years	3.05	30.8
10 years	3.05	30.8

Manager	Title	Age	Since
Maria Alriksson CEO	Chief Executive Officer	43	2020-09-30
Joen Luirink CTO	Chief Tech/Sci/R&D Officer	66	2012-11-02
Mats Fredrik Lundgren CTO	Chief Tech/Sci/R&D Officer	61	2022-04-30

Director	Title	Age	Since
Leif Anders Gunnar Ericsson CHM	Chairman	56	2014-12-31
Fredrik Juserius BRD	Director/Board Member	59	2019-12-31
Ulla Cristina Glad BRD	Director/Board Member	74	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABERA BIOSCIENCE AB	-0.25%	-1.45%	+2.39%	+111.43%	17.41M
LONZA GROUP AG	-1.23%	-1.91%	+0.98%	+17.94%	50.47B
REVOLUTION MEDICINES, INC.	-1.93%	-3.78%	+415.00%	+499.29%	44.56B
IQVIA HOLDINGS INC.	-0.43%	-0.02%	+41.61%	+16.88%	43.08B
BEONE MEDICINES AG	-2.46%	-3.93%	+7.62%	+72.18%	41.7B
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	33.21B
MEDPACE HOLDINGS, INC.	-1.58%	-4.93%	+24.54%	+118.11%	16.77B
ASCENDIS PHARMA A/S	+6.76%	+4.50%	-	-	16.28B
EUROFINS SCIENTIFIC SE	+0.25%	-0.98%	+11.63%	+27.62%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-4.06%	+77.64%	+38.50%	13.92B
Average	-0.34%	-1.11%	+66.64%	+105.42%	27.46B
Weighted average by Cap.	-0.83%	-1.05%	+88.74%	+121.43%

	2024	2025
Net sales	14.63M 1.53M 1.31M 1.23M 1.13M 2.12M 145M 2.13M 5.69M 73.68M 5.73M 5.61M 244M	11.85M 1.24M 1.07M 1M 913K 1.72M 118M 1.73M 4.61M 59.69M 4.64M 4.54M 198M
Net income	-1.1M -115K -98.86K -92.83K -84.74K -159K -10.93M -160K -428K -5.54M -431K -422K -18.34M	-10.45M -1.09M -939K -882K -805K -1.51M -104M -1.52M -4.07M -52.65M -4.1M -4.01M -174M
Net Debt	-6.09M -636K -547K -514K -469K -881K -60.49M -888K -2.37M -30.67M -2.39M -2.34M -102M	-23.49M -2.45M -2.11M -1.98M -1.81M -3.4M -233M -3.42M -9.14M -118M -9.21M -9.01M -392M